• Profile
Close

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

Diabetes, Obesity and Metabolism Jul 04, 2020

Klaff L, Cao D, Dellva MA, et al. - A 26‐week, treat‐to‐target, phase 3 trial was designed to assess the effectiveness and safety of ultra rapid lispro (URLi) vs lispro in adults with type 1 diabetes. Individuals were assigned randomly to double‐blind mealtime URLi (n = 451) or lispro (n = 442), or open‐label post‐meal URLi (n = 329) after an 8‐week lead‐in to optimize basal insulin glargine or degludec, The primary outcome included change from baseline glycated haemoglobin to 26 weeks (non‐inferiority margin 0.4%), with multiplicity‐adjusted objectives for postprandial glucose (PPG) excursions after a meal test. The outcomes revealed that, while superior PPG control was illustrated with mealtime dosing, URLi provided good glycaemic control, with non‐inferiority to lispro confirmed for both mealtime and post‐meal URLi.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay